D
Arbutus Biopharma Corporation
ABUS
$3.28
-$0.235-6.70%
D
Sell
2/7/2024Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D- from E+ on 2/7/2024 due to an increase in the volatility index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D- from E+ on 2/7/2024 due to an increase in the volatility index.
E
Sell
1/23/2024Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to E+ from D- on 1/23/2024 due to a decline in the volatility index.
Arbutus Biopharma Corporation (ABUS) was downgraded to E+ from D- on 1/23/2024 due to a decline in the volatility index.
D
Sell
1/4/2024Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index and total return index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index and total return index.
E
Sell
12/14/2023Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to E+ from D- on 12/14/2023 due to a decline in the volatility index, total return index and valuation index.
Arbutus Biopharma Corporation (ABUS) was downgraded to E+ from D- on 12/14/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
11/27/2023Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D- from E+ on 11/27/2023 due to an increase in the volatility index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D- from E+ on 11/27/2023 due to an increase in the volatility index.
E
Sell
11/9/2023Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to E+ from D- on 11/9/2023 due to a decline in the volatility index, growth index and solvency index. Earnings per share declined from -$0.1029 to -$0.12, EBIT declined 12.26% from -$19.02M to -$21.35M, and operating cash flow declined 11.38% from -$19.56M to -$21.78M.
Arbutus Biopharma Corporation (ABUS) was downgraded to E+ from D- on 11/9/2023 due to a decline in the volatility index, growth index and solvency index. Earnings per share declined from -$0.1029 to -$0.12, EBIT declined 12.26% from -$19.02M to -$21.35M, and operating cash flow declined 11.38% from -$19.56M to -$21.78M.
D
Sell
11/3/2023Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D- from E+ on 11/3/2023 due to an increase in the total return index and volatility index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D- from E+ on 11/3/2023 due to an increase in the total return index and volatility index.
E
Sell
10/18/2023Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to E+ from D- on 10/18/2023 due to a large decline in the growth index, volatility index and total return index. Total revenue declined 30.45% from $6.69M to $4.65M, EBIT declined 10.97% from -$17.14M to -$19.02M, and earnings per share declined from -$0.1011 to -$0.1029.
Arbutus Biopharma Corporation (ABUS) was downgraded to E+ from D- on 10/18/2023 due to a large decline in the growth index, volatility index and total return index. Total revenue declined 30.45% from $6.69M to $4.65M, EBIT declined 10.97% from -$17.14M to -$19.02M, and earnings per share declined from -$0.1011 to -$0.1029.
D
Sell
3/14/2023Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D+ on 3/14/2023 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 4.96 to 4.51.
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D+ on 3/14/2023 due to a decline in the total return index, solvency index and valuation index. The quick ratio declined from 4.96 to 4.51.
D
Sell
2/9/2023Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D- on 02/09/2023.
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D- on 02/09/2023.
D
Sell
2/8/2023Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D+ on 2/8/2023 due to a decline in the total return index and valuation index.
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D+ on 2/8/2023 due to a decline in the total return index and valuation index.
D
Sell
11/11/2022Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 11/11/2022 due to an increase in the volatility index and solvency index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 11/11/2022 due to an increase in the volatility index and solvency index.
D
Sell
11/7/2022Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 11/7/2022 due to a decline in the volatility index and valuation index.
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 11/7/2022 due to a decline in the volatility index and valuation index.
D
Sell
10/21/2022Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 10/21/2022 due to an increase in the volatility index and total return index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 10/21/2022 due to an increase in the volatility index and total return index.
D
Sell
10/6/2022Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 10/6/2022 due to a decline in the volatility index and total return index.
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 10/6/2022 due to a decline in the volatility index and total return index.
D
Sell
9/9/2022Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 9/9/2022 due to an increase in the volatility index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 9/9/2022 due to an increase in the volatility index.
D
Sell
6/1/2022Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 6/1/2022 due to a decline in the volatility index.
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 6/1/2022 due to a decline in the volatility index.
D
Sell
5/17/2022Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D- on 5/17/2022 due to an increase in the volatility index and total return index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D- on 5/17/2022 due to an increase in the volatility index and total return index.
D
Sell
5/13/2022Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 5/13/2022 due to a decline in the volatility index.
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/9/2022Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 5/9/2022 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 13.92 to 5.15.
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 5/9/2022 due to a decline in the volatility index, solvency index and valuation index. The quick ratio declined from 13.92 to 5.15.
D
Sell
5/4/2022Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D- on 05/04/2022.
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D- on 05/04/2022.
D
Sell
5/1/2022Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D+ on 05/01/2022.
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D+ on 05/01/2022.
D
Sell
4/22/2022Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D- on 4/22/2022 due to an increase in the total return index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D- on 4/22/2022 due to an increase in the total return index.
D
Sell
4/20/2022Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 04/20/2022.
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 04/20/2022.
D
Sell
3/21/2022Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 3/21/2022 due to a decline in the total return index.
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 3/21/2022 due to a decline in the total return index.
D
Sell
3/4/2022Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 3/4/2022 due to a large increase in the solvency index, growth index and volatility index. Earnings per share increased from -$0.2394 to -$0.1641, and the quick ratio increased from 12.17 to 13.92.
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 3/4/2022 due to a large increase in the solvency index, growth index and volatility index. Earnings per share increased from -$0.2394 to -$0.1641, and the quick ratio increased from 12.17 to 13.92.
D
Sell
1/31/2022Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 1/31/2022 due to a noticeable decline in the total return index.
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 1/31/2022 due to a noticeable decline in the total return index.
D
Sell
1/10/2022Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 1/10/2022 due to an increase in the volatility index and total return index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 1/10/2022 due to an increase in the volatility index and total return index.
D
Sell
11/23/2021Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D from D- on 11/23/2021.
Arbutus Biopharma Corporation (ABUS) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. Operating cash flow declined 14.47% from -$14.01M to -$16.04M, and earnings per share declined from -$0.2338 to -$0.2394.
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. Operating cash flow declined 14.47% from -$14.01M to -$16.04M, and earnings per share declined from -$0.2338 to -$0.2394.
D
Sell
5/24/2021Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 5/24/2021 due to a decline in the growth index, volatility index and total return index. Operating cash flow declined 19.1% from -$15.01M to -$17.88M, and total revenue declined 11.44% from $2.39M to $2.11M.
Arbutus Biopharma Corporation (ABUS) was downgraded to D from D+ on 5/24/2021 due to a decline in the growth index, volatility index and total return index. Operating cash flow declined 19.1% from -$15.01M to -$17.88M, and total revenue declined 11.44% from $2.39M to $2.11M.
D
Sell
5/17/2021Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 5/17/2021 due to a major increase in the total return index, growth index and volatility index. Total revenue increased 56.66% from $1.52M to $2.39M, and earnings per share increased from -$0.274 to -$0.2336.
Arbutus Biopharma Corporation (ABUS) was upgraded to D+ from D on 5/17/2021 due to a major increase in the total return index, growth index and volatility index. Total revenue increased 56.66% from $1.52M to $2.39M, and earnings per share increased from -$0.274 to -$0.2336.
D
Sell
5/1/2020Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index.
D
Sell
3/6/2020Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 3/6/2020 due to a decline in the efficiency index and volatility index. Total capital declined 12.64% from $87.11M to $76.1M.
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 3/6/2020 due to a decline in the efficiency index and volatility index. Total capital declined 12.64% from $87.11M to $76.1M.
D
Sell
1/10/2020Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D from D- on 1/10/2020 due to an increase in the efficiency index and valuation index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D from D- on 1/10/2020 due to an increase in the efficiency index and valuation index.
D
Sell
1/8/2019Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 1/8/2019 due to a substantial decline in the total return index, growth index and volatility index. Earnings per share declined from $0.01 to -$0.4879.
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 1/8/2019 due to a substantial decline in the total return index, growth index and volatility index. Earnings per share declined from $0.01 to -$0.4879.
D
Sell
8/6/2018Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D from D- on 8/6/2018 due to a significant increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.3589 to $0.01, and operating cash flow increased 11.74% from -$19.97M to -$17.62M.
Arbutus Biopharma Corporation (ABUS) was upgraded to D from D- on 8/6/2018 due to a significant increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.3589 to $0.01, and operating cash flow increased 11.74% from -$19.97M to -$17.62M.
D
Sell
4/19/2017Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D- from E+ on 4/19/2017 due to an increase in the total return index and volatility index.
Arbutus Biopharma Corporation (ABUS) was upgraded to D- from E+ on 4/19/2017 due to an increase in the total return index and volatility index.
E
Sell
3/24/2017Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to E+ from D- on 3/24/2017 due to a major decline in the growth index, efficiency index and solvency index. Net income declined 1,016.08% from -$19.6M to -$218.7M, earnings per share declined from -$0.3652 to -$4.0121, and total revenue declined 125.19% from $774 to -$195.
Arbutus Biopharma Corporation (ABUS) was downgraded to E+ from D- on 3/24/2017 due to a major decline in the growth index, efficiency index and solvency index. Net income declined 1,016.08% from -$19.6M to -$218.7M, earnings per share declined from -$0.3652 to -$4.0121, and total revenue declined 125.19% from $774 to -$195.
D
Sell
12/23/2016Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 12/23/2016 due to a decline in the total return index, growth index and volatility index.
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 12/23/2016 due to a decline in the total return index, growth index and volatility index.
D
Sell
11/4/2016Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to D from D- on 11/4/2016 due to an increase in the growth index, solvency index and volatility index. Total revenue increased 150.49% from $309 to $774, earnings per share increased from -$2.466 to -$0.37, and EBIT increased 17.59% from -$23.02M to -$18.98M.
Arbutus Biopharma Corporation (ABUS) was upgraded to D from D- on 11/4/2016 due to an increase in the growth index, solvency index and volatility index. Total revenue increased 150.49% from $309 to $774, earnings per share increased from -$2.466 to -$0.37, and EBIT increased 17.59% from -$23.02M to -$18.98M.
D
Sell
8/10/2016Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 8/10/2016 due to a large decline in the growth index, volatility index and efficiency index. Net income declined 718.95% from -$15.87M to -$130M, earnings per share declined from -$0.3088 to -$2.466, and EBIT declined 51.7% from -$15.18M to -$23.02M.
Arbutus Biopharma Corporation (ABUS) was downgraded to D- from D on 8/10/2016 due to a large decline in the growth index, volatility index and efficiency index. Net income declined 718.95% from -$15.87M to -$130M, earnings per share declined from -$0.3088 to -$2.466, and EBIT declined 51.7% from -$15.18M to -$23.02M.
D
Sell
3/11/2016Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index, efficiency index and total return index. Total capital declined 1.11% from $553.81M to $547.68M.
Arbutus Biopharma Corporation (ABUS) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index, efficiency index and total return index. Total capital declined 1.11% from $553.81M to $547.68M.
C
Hold
3/7/2016Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to C- from D+ on 3/7/2016 due to a substantial increase in the volatility index and valuation index.
Arbutus Biopharma Corporation (ABUS) was upgraded to C- from D+ on 3/7/2016 due to a substantial increase in the volatility index and valuation index.
D
Sell
1/12/2016Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D+ from C- on 1/12/2016 due to a decline in the total return index.
Arbutus Biopharma Corporation (ABUS) was downgraded to D+ from C- on 1/12/2016 due to a decline in the total return index.
C
Hold
12/28/2015Upgraded
Arbutus Biopharma Corporation (ABUS) was upgraded to C- from D+ on 12/28/2015 due to an increase in the total return index and valuation index.
Arbutus Biopharma Corporation (ABUS) was upgraded to C- from D+ on 12/28/2015 due to an increase in the total return index and valuation index.
D
Sell
11/9/2015Downgrade
Arbutus Biopharma Corporation (ABUS) was downgraded to D+ from C- on 11/9/2015 due to a significant decline in the volatility index, solvency index and total return index.
Arbutus Biopharma Corporation (ABUS) was downgraded to D+ from C- on 11/9/2015 due to a significant decline in the volatility index, solvency index and total return index.
C
Hold
5/8/2015Upgraded
Tekmira Pharmaceuticals Corporation (TKMR) was upgraded to C- from D+ on 5/8/2015 due to a major increase in the efficiency index, valuation index and growth index. Total capital increased 574.38% from $88.04M to $593.69M, operating cash flow increased 160.63% from -$6.85M to -$17.84M, and net income increased 94.37% from -$6.17M to -$11.99M.
Tekmira Pharmaceuticals Corporation (TKMR) was upgraded to C- from D+ on 5/8/2015 due to a major increase in the efficiency index, valuation index and growth index. Total capital increased 574.38% from $88.04M to $593.69M, operating cash flow increased 160.63% from -$6.85M to -$17.84M, and net income increased 94.37% from -$6.17M to -$11.99M.
D
Sell
5/4/2015Downgrade
Tekmira Pharmaceuticals Corporation (TKMR) was downgraded to D+ from C- on 5/4/2015 due to a noticeable decline in the volatility index and total return index.
Tekmira Pharmaceuticals Corporation (TKMR) was downgraded to D+ from C- on 5/4/2015 due to a noticeable decline in the volatility index and total return index.
C
Hold
3/25/2015Upgraded
Tekmira Pharmaceuticals Corporation (TKMR) was upgraded to C- from D+ on 3/25/2015 due to a large increase in the total return index, efficiency index and volatility index.
Tekmira Pharmaceuticals Corporation (TKMR) was upgraded to C- from D+ on 3/25/2015 due to a large increase in the total return index, efficiency index and volatility index.
D
Sell
1/14/2015Downgrade
Tekmira Pharmaceuticals Corporation (TKMR) was downgraded to D+ from C- on 1/14/2015 due to a decline in the valuation index and total return index.
Tekmira Pharmaceuticals Corporation (TKMR) was downgraded to D+ from C- on 1/14/2015 due to a decline in the valuation index and total return index.
C
Hold
11/7/2014Upgraded
Tekmira Pharmaceuticals Corporation (TKMR) was upgraded to C- from D on 11/7/2014 due to a large increase in the volatility index and valuation index.
Tekmira Pharmaceuticals Corporation (TKMR) was upgraded to C- from D on 11/7/2014 due to a large increase in the volatility index and valuation index.
D
Sell
3/13/2014Downgrade
Tekmira Pharmaceuticals Corporation (TKMR) was downgraded to D from B on 3/13/2014 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 163.16% from -$3.62M to $2.28M, earnings per share declined from -$0.4044 to -$0.165, and net income declined 49.68% from -$5.86M to -$2.95M.
Tekmira Pharmaceuticals Corporation (TKMR) was downgraded to D from B on 3/13/2014 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 163.16% from -$3.62M to $2.28M, earnings per share declined from -$0.4044 to -$0.165, and net income declined 49.68% from -$5.86M to -$2.95M.
NASDAQ
04/04/2025 12:54PM Eastern
Quotes delayed
